Sherbrooke Park Advisers LLC Purchases New Shares in The Clorox Company (NYSE:CLX)

Sherbrooke Park Advisers LLC purchased a new position in shares of The Clorox Company (NYSE:CLX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 3,953 shares of the company's stock, valued at approximately $642,000.

A number of other hedge funds also recently modified their holdings of the business. Brooklyn Investment Group grew its holdings in shares of Clorox by 163.8% during the fourth quarter. Brooklyn Investment Group now owns 153 shares of the company's stock worth $25,000 after buying an additional 95 shares in the last quarter. Redwood Park Advisors LLC bought a new position in shares of Clorox in the 4th quarter valued at about $26,000. Millstone Evans Group LLC acquired a new position in shares of Clorox during the 4th quarter worth about $31,000. Asset Planning Inc bought a new stake in Clorox in the fourth quarter valued at approximately $32,000. Finally, GKV Capital Management Co. Inc. bought a new position in shares of Clorox during the 4th quarter worth approximately $32,000. Institutional investors and hedge funds own 78.53% of the company's stock.

Insider Activity

In other news, Director Pierre R. Breber purchased 4,000 shares of the business's stock in a transaction on Wednesday, May 7th. The shares were acquired at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the acquisition, the director now owns 4,000 shares in the company, valued at approximately $546,280. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.57% of the company's stock.

Clorox Price Performance

Shares of CLX traded up $0.69 during trading hours on Tuesday, hitting $135.53. 1,678,112 shares of the company were exchanged, compared to its average volume of 1,326,272. The company has a market cap of $16.70 billion, a price-to-earnings ratio of 37.03, a P/E/G ratio of 2.62 and a beta of 0.60. The firm's fifty day moving average is $140.80 and its 200 day moving average is $153.09. The Clorox Company has a fifty-two week low of $127.60 and a fifty-two week high of $171.37. The company has a quick ratio of 0.60, a current ratio of 0.94 and a debt-to-equity ratio of 20.52.

Clorox (NYSE:CLX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.12). The company had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.74 billion. Clorox had a return on equity of 316.87% and a net margin of 6.38%. The firm's quarterly revenue was down 8.0% on a year-over-year basis. During the same quarter last year, the company posted $1.71 earnings per share. On average, equities analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Clorox Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, May 9th. Shareholders of record on Wednesday, April 23rd were given a $1.22 dividend. The ex-dividend date was Wednesday, April 23rd. This represents a $4.88 dividend on an annualized basis and a dividend yield of 3.60%. Clorox's dividend payout ratio (DPR) is presently 87.61%.

Analysts Set New Price Targets

A number of research firms have commented on CLX. Wells Fargo & Company reduced their price objective on shares of Clorox from $145.00 to $142.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Citigroup lowered their price target on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating on the stock in a report on Monday, April 14th. Morgan Stanley reduced their price objective on Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. UBS Group lowered their target price on Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Finally, JPMorgan Chase & Co. reduced their price target on Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a research note on Tuesday, May 6th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $151.23.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.